Cargando…

The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study

BACKGROUND: Randomized controlled trials (RCTs) have demonstrated a survival benefit for adjuvant platinum-based chemotherapy after resection of locoregional non-small cell lung cancer (NSCLC). The relative benefits and harms and optimal approach to treatment for NSCLC patients who have major comorb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leiter, Amanda, Kong, Chung Yin, Gould, Michael K., Kale, Minal S., Veluswamy, Rajwanth R., Smith, Cardinale B., Mhango, Grace, Huang, Brian Z., Wisnivesky, Juan P., Sigel, Keith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665372/ https://www.ncbi.nlm.nih.gov/pubmed/36378625 http://dx.doi.org/10.1371/journal.pone.0263911

Ejemplares similares

Immunotherapy Outcomes in Individuals With Non–Small Cell Lung Cancer and Poor Performance Status
por: Veluswamy, Rajwanth, et al.
Publicado: (2022)

Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities
por: Sigel, Keith, et al.
Publicado: (2021)

Impact of diabetes on stage I lung cancer treatment patterns and prognosis in older adults: A population-based cohort study
por: Leiter, Amanda, et al.
Publicado: (2023)

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States
por: Veluswamy, Rajwanth, et al.
Publicado: (2022)

Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl
por: Kong, Chung Yin, et al.
Publicado: (2018)

Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden
por: Criss, Steven D., et al.
Publicado: (2020)

Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality
por: Song, Xiaoyu, et al.
Publicado: (2021)

Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results‐Medicare analysis of 5235 patients
por: Ni, Katherine, et al.
Publicado: (2021)

No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
por: Kang, Nai-Wen, et al.
Publicado: (2022)

The Effects of Comorbidity on the Benefits and Harms of Treatment for Chronic Disease: A Systematic Review
por: Fried, Terri R., et al.
Publicado: (2014)

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study
por: Wisnivesky, Juan P, et al.
Publicado: (2011)

3363 Prognostic Value of Immune-Related Biomarkers in Resected Non-Small Cell Lung Cancer
por: Veluswamy, Rajwanth R, et al.
Publicado: (2019)

A tool to balance benefit and harm when deciding about adjuvant therapy
por: Knops, A M, et al.
Publicado: (2009)

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy
por: Oronsky, Bryan, et al.
Publicado: (2016)

Copper-lowering agents as an adjuvant in chemotherapy
por: Kadu, Pramod, et al.
Publicado: (2021)

PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis
por: Tuminello, Stephanie, et al.
Publicado: (2020)

Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)

Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis
por: Tuminello, Stephanie, et al.
Publicado: (2022)

Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy
por: Fulop, Daniel J., et al.
Publicado: (2023)

Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis
por: Tuminello, Stephanie, et al.
Publicado: (2019)

Clinically significant mutations in HIV-infected patients with lung adenocarcinoma
por: Thaler, Jonathan, et al.
Publicado: (2017)

Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection
por: Wisnivesky, Juan P., et al.
Publicado: (2021)

Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer
por: Teufel, Andreas, et al.
Publicado: (2015)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

TRIOLOGY ACS: No benefit/No harm
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

Benefits and harms of mammography screening
por: Løberg, Magnus, et al.
Publicado: (2015)

Prognosis in HIV-infected patients with non-small cell lung cancer
por: Sigel, K, et al.
Publicado: (2013)

Lung cancer incidence among world trade center rescue and recovery workers
por: Sigel, Keith, et al.
Publicado: (2022)

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
por: Stål, O., et al.
Publicado: (1994)

Preoperative Splenic Density for the Prediction of Survival and Adjuvant Chemotherapy Benefits in Gastric Cancer
por: Zhang, Wei-teng, et al.
Publicado: (2020)

Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer
por: Lee, Mok-Won, et al.
Publicado: (2021)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

The Association of Health Literacy with Illness and Medication Beliefs among Patients with Chronic Obstructive Pulmonary Disease
por: Kale, Minal S., et al.
Publicado: (2015)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Critical Overview on the Benefits and Harms of Aspirin
por: Kwok, Chun Shing, et al.
Publicado: (2010)

Adjuvant chemotherapy
por: Glimelius, B.
Publicado: (2013)

Could Adjuvant Chemotherapy after Surgery Benefit Elderly Patients with Advanced Gastric Cancer?
por: Jeong, Jin Woon, et al.
Publicado: (2016)

Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer
por: Liu, Qi, et al.
Publicado: (2019)

Promotion of the Warburg effect is associated with poor benefit from adjuvant chemotherapy in colorectal cancer
por: Kitazawa, Masashi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hrh4f4ia3nela4b4egq2den04n